Recent Updates — ABT
Abbott Laboratories announced its intention to separate its global nutrition business into an independent, publicly traded company through a tax-free distribution to shareholders. The new entity will generate approximately $8.5 billion in annual sales and feature iconic brands including Ensure, Similac, and Pedialyte. Abbott expects the transaction to close by the end of 2027, subject to regulatory approvals and board approval. Following the separation, Abbott will retain its medical devices, diagnostics, and established medicines portfolio with projected sales of approximately $42 billion. Daniel Salvadori is set to become CEO of the new Nutrition company. This strategic move aims to unlock value by allowing both entities to pursue distinct growth strategies aligned with their specific investment profiles.
Abbott Laboratories operates as a global healthcare leader providing medical devices, diagnostics, established medicines, and nutrition products.
Abbott Laboratories reported third-quarter 2026 results with total sales increasing 14.5 percent to $13,013 million and comparable sales growth of 7.0 percent. The company posted GAAP diluted earnings per share of $0.53, while adjusted diluted EPS excluding specified items reached $1.42. Abbott reaffirmed its full-year 2026 adjusted diluted EPS guidance range, tightening it to $5.50–$5.55 from the previous midpoint, and projected full-year comparable sales growth of approximately 6.0 percent. Additionally, the board declared a quarterly dividend of $0.63 per share, payable November 16, 2026, to shareholders of record as of October 15, 2026. Abbott operates in the global healthcare sector, developing and manufacturing medical devices, diagnostics, nutritionals, and branded generic medicines.
Abbott Laboratories announced on August 20, 2026, that it entered into agreements to resolve the Gill lawsuit and necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million. This settlement avoids paying approximately $600 million representing the original $495 million judgment plus accrued interest. The agreements are a compromise of disputed claims and not an admission of liability. Following this resolution, approximately 1,700 lawsuits remain pending in federal and state courts involving claims on behalf of roughly 12,700 individual infants. Abbott operates as a global healthcare leader providing diagnostics, medical devices, nutritionals, and branded generic medicines.
Abbott Laboratories reported second-quarter 2026 results with reported sales growth of 13.0 percent and adjusted diluted EPS of $1.31. The company raised its full-year 2026 adjusted diluted EPS guidance to a range of $5.45 to $5.60, compared to the previous range of $5.38 to $5.58. Abbott returned $2.1 billion to shareholders in the second quarter through dividends and share repurchases. Abbott Laboratories is a global healthcare leader providing diagnostics, medical devices, nutritionals, and branded generic medicines.
Abbott Laboratories shareholders approved the 2026 Incentive Stock Program, which authorizes the issuance of up to 140 million common shares to replace the company's existing 2017 program. Additionally, the company expanded its Board of Directors to thirteen members and appointed Kevin Conroy to the Board. These updates refresh Abbott's equity compensation framework and governance structure for the upcoming ten-year term.
A federal court has preliminarily approved a proposed settlement in the consolidated shareholder derivative litigation regarding Abbott Laboratories' infant formula issues. This development marks a significant step toward resolving legal claims against the company's directors and officers, potentially reducing long-term legal uncertainty and liability for the firm.